24445-44-1

Basic information

• Product Name: 2,3-dihydro-1H-inden-2-yl(methyl)amine(SALTDATA: HCl)
• Synonyms: 2,3-dihydro-1H-inden-2-yl(methyl)amine(SALTDATA: HCl);2,3-dihydro-1H-inden-2-yl(Methyl)aMine;JPC 6811;N-Methylindan-2-amine;N-2,3-Dihydro-1H-inden-2-yl-N-methylamine hydrochloride
• CAS NO: 24445-44-1
• Molecular Formula: C₁₀H₁₃N
• Molecular Weight: 183.67786
• Mol File: 24445-44-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 236℃
• Flash Point: 98℃
• Appearance: /
• Density: 1.01
• PKA: 9.97±0.20(Predicted)
• CAS DataBase Reference: 2,3-dihydro-1H-inden-2-yl(methyl)amine(SALTDATA: HCl)(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-dihydro-1H-inden-2-yl(methyl)amine(SALTDATA: HCl)(24445-44-1)
• EPA Substance Registry System: 2,3-dihydro-1H-inden-2-yl(methyl)amine(SALTDATA: HCl)(24445-44-1)

Safety Data

• Hazardous Substances Data: 24445-44-1(Hazardous Substances Data)

Usage

General Description

2,3-dihydro-1H-inden-2-yl(methyl)amine (SALTDATA: HCl) is a chemical compound that consists of an indenylmethylamine group. 2,3-dihydro-1H-inden-2-yl(methyl)amine(SALTDATA: HCl) is commonly found in pharmaceutical research and development as a potential candidate for drug discovery due to its structural and biological properties. The addition of hydrochloride salt (HCl) is often used to enhance the solubility and stability of the compound, making it more suitable for pharmaceutical applications. This chemical entity has the potential for further studies and applications in the field of medicinal chemistry.

Upstream product

• 615-13-4 2-indanone 
• 74-89-5 methylamine 
• 2338-18-3 2-aminoindane hydrochloride 
• 24446-27-3 indan-2-yl-carbamic acid ethyl ester 
• 2975-41-9 2,3-dihydro-1H-inden-2-amine 
• 541-41-3 chloroformic acid ethyl ester 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 82985-09-9 2-N-n-Propylaminoindan 
• 118623-88-4 benzyl-indan-2-yl-methyl-amine; hydrochloride 
• 138006-28-7 4-[N-(indan-2-yl)-N-methyl]aminomethyl-1-benzoylpiperidine hydrochloride 

Relevant articles and documents

Glycinamide derivative as well as preparation method and application thereof

The invention discloses a glycinamide derivative as well as a preparation method and application thereof. The derivative with a structural formula as shown in the following formula (I) is provided; and in the formula, R1 is selected from Cl and H, R2 is one selected from H, CH3 and CH2CH3; and X is one selected from NHCH3, NHCH2CH3, N (CH2CH3) 2, a pyrrolyl group and a piperidyl group. During preparation, different phenyl glutaric acid compounds are selected as raw materials and are respectively subjected to amidation reaction twice with an aminoindane hydrochloride derivative and an ethylenediamine derivative to obtain a target derivative. The prepared derivative or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition thereof can be used as an S-adenosyl homocysteine hydrolase inhibitor for the development of antitumor drugs .

TACHYKININ RECEPTOR ANTAGONISTS

The present invention relates to selective NK-1 receptor antagonists of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins.

Synthesis and structure-activity relationships of trisubstituted phenyl urea derivatives as neuropeptide Y5 receptor antagonists

1-((1R,2R)-2-Hydroxy-1-methyl-2-phenylethyl)-1-methyl-3-(4-phenoxyphenyl)urea (1) was identified as a hit from the screening of the neuropeptide Y5 (NPY5) receptor. This lead was optimized for in vitro potency by changing the stereochemistry, the phenylethyl segment, the urea portion, and the 4-phenoxyphenyl group on the molecule. Over 40 analogues of 1 were prepared to study the structure-activity relationship for this series. The most potent compounds in this class have IC50S less than 0.1 nM at the NPY5 receptor (e.g., 40f, 44a, and 47). To determine the functional activity for this series of compounds, selected analogues were tested in a cellular assay measuring forskolin-induced cyclic AMP accumulation in 293 cells transfected with the human NPY5 receptor. All urea analogues tested in the functional assay acted as antagonists (e.g., 1, 32, 40a, and 44e).